upsid enhanc visibl
outlook
ep beat driven better expect
top-line org sale off-set continu gm pressur
bp result improv profit
rais pt prior base ep
upsid driven better expect top-line hsi ep
ahead expect mse/consensu driven organ sale
vs mse ebit upsid gm remain pressur bp
due higher freight cost unfavor mix invest trade
promotions/packag sg expens in-lin expect vs
mse na organ sale declin due promot time well
lap elev inventori level last year top-line solid org
sale driven cc growth brazil mexico india reiter
guidanc organ sale toward low end rang
slightli ii benefit acquisit vs prior due
divestitur golden monkey tyrel iii gm bp iv ep
result increas visibl guidanc
guidanc impli sharp acceler ep growth mse vs
necessari achiev fy outlook howev encourag
sever develop second quarter enhanc visibl
full year outlook includ continu improv profit
mm profit ytd ii announc price increas across portfolio
begin meaning flow start iii
compani visibl strong holiday order increas retail shelf space
addit result benefit recent innov rees
outrag continu brand build
increas ep reflect upsid improv profit
divestitur rais pt vs prior increas
ep vs prior base organ sale
improv profit mm vs mm prior top-line
headwind golden monkey/tyrel divestitur rais pt
base ep moder hsd premium center-stor peer
histor premium given slow rel growth profil
food unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
risk-reward view fundament advantag reflect valuat
risk-reward view fundament advantag reflect valuat
pt reflect ev/ebitda price-to-earnings hsd premium
innov favor categori dynam lead upsid increment
innov strong nam confectionari categori growth recoveri
intern result organ sale growth deflationari input cost
moder promot environ lead bp margin expans
base ev/ebitda price-to-earnings
base ev/ebitda price-to-earnings
modest recoveri organ sale follow modest volum net price
realiz org sale expect na organ growth acceler
modestli stabil recov drive
organ sale growth margin expand ep grow msd
organ sale deceler volum deceler
growth remain weak input cost inflat increas competit promot
pressur result flat yoy ebit margin ep flat
underweight top-line growth
remain tepid face increasingli
difficult top-line growth outlook due
innov pipelin mount us
limit upsid consensu margin
expect cautiou
margin expans prospect
benefit restructur save
favor input cost upsid
constrain greater retail pressur
supplier neg mix impact
snackfect elev reinvest
valuat among risk
post-reform tax landscap
project ep ebitda growth
across packag food sector
shift valu premium
weaker expect guidanc
risk achiev price
success innov
exhibit hsi ntm price-to-earnings std deviat histor
exhibit trade std deviat histor
exhibit ms forecast organ growth nam
exhibit ad spend yoy
exhibit gross margin contract bp
sale
sell market administr
sg sale
incom incom tax
provis incom tax
incom oper
fx impact ep
sale
equival
prepaid
accru liabil tax
current portion ltd
net issuanc repurchas common
total liabiltii stockhold equiti
reconcili net incom
net chang wc
net flow provid use oper activ
dec inc a/r
dec inc inv
dec inc assets/liab
flow provid use invest activ
net flow use invest activ
flow provid use financ activ
proce ipo
net chang short-term borrow
repay long-term debt
exercis stock option
net flow use provid financ activ
chang equival
equival begin period
equival end period
